Pomegra
Moderna shares fell about 6% to near $190 after Citi cut the stock to Sell with an $80 target, saying a 223% rally overshot what cancer vaccine sales can justify.
- Moderna fell 6% to 6.8% on Sept. 30 after Citi moved it from Neutral to Sell and set an $80 target, about 60% below Tuesday's close.
- The stock has gained 223% since Aug. 19 on melanoma vaccine data and is up nearly 590% in 2026.
- Citi says a 100% success rate in Moderna's lead oncology program would support only about $100 a share.
Lead
Moderna (NASDAQ: MRNA) fell between 6% and 6.8% on Wednesday, Sept. 30, to roughly $190. The drop followed a downgrade from Citi to Sell from Neutral. Citi raised its price target to $80 from $60, which still implies about 60% downside from Tuesday's close near $200. The move cut into one of the sharpest rallies among large biotech company stocks this year.What Did Citi Say About Moderna's Valuation?
Citi said the share price reflects expectations that Moderna's cancer program will succeed across many tumor types, and that its model does not support them. Analyst Geoff Meacham wrote that he could not justify the valuation through public-company comparisons or pipeline net present value.
Citi estimates Moderna would need about $13 billion in annual oncology revenue to justify the current price. Its own model projects a fraction of that. Even a 100% probability of success for the lead cancer program, intismeran autogene, would support a value of about $100 a share, roughly half the recent trading level.
Citi accepts that intismeran could become a leading melanoma treatment. It argues that melanoma success does not establish results in lung, kidney or bladder cancers.
Why Did Moderna Rally So Sharply Before the Downgrade?
Moderna rallied because late-stage data for intismeran, a personalized mRNA cancer vaccine, showed improved recurrence prevention in melanoma. The therapy is given with Merck's (NYSE: MRK) Keytruda and was tested in more than 1,100 patients in the INTerpath-001 trial.
The stock has gained 223% since Aug. 19, against a 52-week low of $22.28 and a recent high of about $209. Detailed trial results have not been released. They are expected at the ESMO meeting in late October, the next major catalyst.
How Did Peers and the Broader Market React?
Peers and the wider market were steady. The S&P 500 rose 0.41% and the Nasdaq gained 0.68%. The iShares Biotech ETF (IBB) was up 0.04%, so the Moderna decline did not spread to the biotech etf group. Merck slipped 1.70% to $146.74, while Pfizer (NYSE: PFE) gained 0.31% to $28.81.
Other Pressures on the Stock
A legal ruling added to the day's negative news. On Sept. 28 a Delaware federal court denied Moderna's motion to dismiss a patent infringement suit over mRNA-related intellectual property. No damages figure has been set.
Fundamentals sit far from the share price. Moderna reports annual revenue of about $1.94 billion against a net loss of $2.82 billion. Commercial vaccine demand has weakened. The average analyst price target is $117.66, with a range of $40 to $170, and the consensus rating is Hold.
What Comes Next for Moderna Shares?
The ESMO presentation in late October is the next test of whether the INTerpath-001 results support expectations beyond melanoma. A strong data set with signs of benefit in other tumor types would narrow the gap Citi describes. Results limited to melanoma would leave the stock dependent on the broad oncology success the downgrade questions.
The Delaware case will continue. Moderna is also still burning cash while it funds late-stage oncology trials.
Outlook
Citi's downgrade turned a one-way rally into a debate over how much of Moderna's cancer pipeline is already in the price. Near $190, the stock is valued well above Citi's $80 target and above the $117.66 average target across analysts. The late-October ESMO data is the next event likely to reset expectations.
Mentioned tickers: MRNA, MRK, PFE, C, IBB
